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The value of surgery to establish histological diagnosis and 
define the molecular profile of low-grade gliomas to inform fur-
ther management (i.e. observation with MRI vs radiotherapy 
and/or chemotherapy) is clear. Moreover, there is an almost 
general agreement that maximal safe resection should be 
attempted early on in patients presenting with neurological 
symptoms (more commonly seizures) and a suspected low-
grade glioma on MRI.1 Even if there has been no randomized 
controlled trial that evaluated the extent of resection in these 
tumors, several retrospective studies have suggested that a 
significant improvement in both progression-free (PFS) and 
overall survival (OS) is associated with an increasing amount 
of tumor removal.2,3 However, only a minority of studies have 
analyzed the importance of extent of resection based on a more 
precise volumetric assessment of the residual tumor after sur-
gery.4–6 Following the new World Health Organization (WHO) 
Classification of Brain Tumors in 2016, a new question has 
arisen: whether the feasibility and value of the extent of resec-
tion are influenced by the molecular profile.
In this issue of Neuro-Oncology Wijnenga et al7 from the 
Netherlands report the results of a retrospective study on 228 
adult patients with WHO II supratentorial glioma in whom they 
evaluated the impact of the postoperative tumor volume, cor-
rected for molecular profile, on OS. Pre- and postoperative 
tumor volumes were assessed with semi-automatic software 
on T2-weighted MRI images, and a targeted next-generation 
sequencing was used for a molecular classification of tumors. 
Complete or near complete resection was achieved in 39% of 
patients. Overall, after multivariable analysis, postoperative 
tumor volume, as primary measure of the extent of resection, 
was significantly associated with OS with HR of 1.01 (95% CI 
1.002-1.02, p=0.016) per cm3 increase in volume. Notably, 
a strong effect on OS was seen in patients with no detect-
able tumor after resection. These findings are in line with the 
results of a previous smaller post-hoc analysis performed by 
a University of California, San Francisco (UCSF) group,8 that 
reported a significant association of postoperative tumor vol-
ume with OS after stratification by molecular factors (1p/19q 
codeletion and IDH 1 mutation). In particular, every 10 cm3 of 
increase in postoperative volume was associated with shorter 
OS.
Interestingly, in the Wijnenga study7 the negative effect on 
OS of any residual tumor after surgery was more evident in 
IDH mutated astrocytomas compared with IDH-mutated and 
1p/19q-codeleted oligodendrogliomas. An explanation could 
be that the amount of residual tumor cells is more critical in 
astrocytomas, due to an inherent risk of malignant progres-
sion toward glioblastoma, than in oligodendrogliomas, which 
conversely are intrinsically more indolent and responsive to 
chemotherapy with alkylating agents. However, this hypoth-
esis needs confirmation in prospective datasets with a dur-
ation of follow-up longer than that of the present study (5.79 
years). Due to the retrospective nature of the Dutch study, the 
MRI protocol, postoperative treatments and timing of follow-
up evaluations were heterogeneous, thus precluding a reliable 
analysis of the influence of the extent of resection on PFS.
Two important questions need to be answered by future 
studies. First, what is the value of the extent of resection in IDH 
wild-type grade II gliomas? These tumors are more aggressive 
than IDH-mutated counterparts but somewhat heterogeneous 
in terms of prognosis.9 Both the UCSF and Dutch studies were 
not able to investigate this issue due to the small sample size. 
A second, more general question is whether the same consid-
erations in terms of the importance of the extent of resection 
can apply to IDH-mutated grade III gliomas, whose outcome 
seems similar to that of IDH-mutated grade II tumors.
The modern tools in neurosurgical oncology (intraoperative 
mapping, awake surgery, intraoperative MRI) have increased 
the feasibility of more radical resections, and thus new con-
cepts of management have been hypothized.10 Supratotal 
resection, i.e. resection extending beyond the MRI signal 
abnormalities, for tumors in non-eloquent areas has been 
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proposed with the aim of avoiding potentially toxic adju-
vant therapies. Moreover, reoperation either at progression 
after initial observation with MRI or even as a second-look 
surgery following an initial incomplete resection, is increas-
ingly used in neurosurgical centers with specific expertise 
in lower-grade gliomas. However, only well-designed pro-
spective studies with uniform techniques and methodology 
can answer some critical questions, such as whether a total/
supratotal resection is better in terms of survival compared 
with a near total/subtotal resection, and whether the clinical 
benefit of the different types of resection is the same or not 
in the different molecular subgroups.
Finally, it will be crucial when designing new studies to 
be aware that the preservation of cognitive functions and 
quality of life is at least as important as the improvement 
of survival.
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